Kestra Medical Technologies, a Kirkland, WA-based wearable medical device and digital healthcare company, raised $196M in funding.
The round was led by Andera Partners, Ally Bridge Group, Longitude Capital and Omega Funds with participation from new investors, funds and accounts advised by T. Rowe Price Investment Management, Inc., Eventide Asset Management, Gilmartin Capital, Bain Capital and Endeavour Vision. In conjunction with the financing, Kevin Reilly from Ally Bridge Group, Maxwell Bikoff from Longitude Capital, and Francesco Draetta from Omega Funds will join the Kestra Board of Directors.
The company intends to use the funds to support the expansion of their commercial organization and advance its mission of protecting at-risk patients with its modern Wearable Cardioverter Defibrillator (WCD).
Led by CEO and President Brian Webster, Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects cardiac patients with diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and mobile. The ASSURE system represents the next generation of cardiac monitoring and defibrillation therapy. In addition to providing autonomous detection and defibrillation for ventricular arrhythmias, it can also detect and record other clinically significant arrhythmias which may require clinical intervention. The ASSURE system has established reimbursement and broad insurance coverage in the U.S.
FinSMEs
24/07/2024